Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy

British Journal of Nutrition

Volumn 100, Issue 6, 2008, Pages 1179-1182

  Premkumar, Vummidi Giridhar ^a   Yuvaraj, Srinivasan ^a   Shanthi, Palanivel ^a   Sachdanandam, Panchanatham ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Breast cancer; Co enzyme Q10; DNA repair; Methylation; Niacin; Riboflavin; Tamoxifen

Indexed keywords

KANEKA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINIC ACID; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RIBOFLAVIN; TAMOXIFEN; TAMOXIFEN CITRATE; UBIDECARENONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DNA; DRUG DERIVATIVE; UBIQUINONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; BREAST TUMOR; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; SINGLE BLIND PROCEDURE;

ZEA MAYS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; DNA METHYLATION; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NIACIN; POLY(ADP-RIBOSE) POLYMERASES; RIBOFLAVIN; SINGLE-BLIND METHOD; TAMOXIFEN; UBIQUINONE;

EID: 56349105137     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114508968276     Document Type: Article

References (23)

1. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornande T & Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87 645-651.
2. van Dalen A, Heering KJ, Barak V, et al. (1996) Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. Breast 5, 82-88.
3. Hemminki K, Rajaniemi H, Koskinen M & Hansson J (1997) Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients. Carcinogenesis 18, 9-13.
4. Kameshita I, Matsuda Z, Taniguchi T & Shizuta Y (1984) Poly (ADP-ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain. J Biol Chem 259, 4770-4776.
5. D'Amours D, Desnoyers S. D'Silva I & Poirier GG (1999) Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342, 249-268.
6. Jones PA & Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428.
7. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C & Widschwendter M (2003) DNA methylation in serum of breast cancer patients: An independent prognostic marker. Cancer Res 63, 7641-7645.
8. Sambrook J. Fritsch EF & Maniatis T (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., pp. E3-E4, New York: Cold Spring Harbor Laboratory.
9. Herman JG, Graff JR, Myöhänen S, Nelkin BD & Baylin SB (1996) Tamoxifen-induced DNA: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93, 9821-9826.
10. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S & Argani P (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107, 970-975.
11. Lowry OH, Rosebrough NJ, Farr AL & Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193, 265-275.
12. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
13. Boyonoski AC, Spronck JC, Jacobs RM, Shah GM, Poirier GG & Kirkland JB (2002) Pharmacological intakes of niacin increase bone marrow poly(ADP-ribose) and the latency of ethylnitrosourea-induced carcinogenesis in rats. J Nutr 132, 115-120.
14. Perumal SS, Shanthi P & Sachdanandam P (2005) Energy-modulating vitamins - a new combinatorial therapy prevents cancer cachexia in rat mammary carcinoma. Br J Nutr 93, 901-909.
15. Pangrekar J, Krishnaswamy K & Jagadeesa V (1993) Effects of riboflavin deficiency and riboflavin administration on carcinogen-DNA binding. Food Chem Toxicol 31, 745-750.
16. Webster RP, Gawde MD & Bhattacharya RK (1996) Modulation of carcinogen-induced DNA damage and repair enzyme activity by dietary riboflavin. Cancer Lett 98, 129-135.
17. 10 therapy. Mutagenesis 19, 43-49.
18. 10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J 15, 1425-1427.
19. 10: Effects on lipid peroxidation and antioxidants in mitochondria. Chem Biol Interact 152, 49-58.
20. 10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clin Biochem 40, 623-628.
21. 10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull 30, 367-370.
22. Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG & Sachdanandam P (2007) Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic Clin Pharmacol Toxicol 100 387-391.
23. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G & Widschwendter M (2005) Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65, 1141-1145.